Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.
CSPC Pharmaceutical Group has introduced a new 2026 Share Award Scheme after the existing 2018 plan neared its purchase limit of on-market shares, capped at 2% of the company’s issued share capital at its launch. The 2018 scheme, which has 64,019,868 shares still available for grant and 53,318,500 unvested awards outstanding, will continue in force until August 2028, with all awards satisfied via on-market share purchases rather than new share issuance.
The newly adopted 2026 scheme, effective for 10 years from its adoption date, is designed to give selected participants a proprietary interest in the company and incentivize them to meet performance goals. By structuring the awards to be settled only with existing shares and not requiring shareholder approval, CSPC aims to strengthen employee retention and alignment with shareholders while avoiding dilution, in compliance with Hong Kong listing rules on share schemes.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-incorporated pharmaceutical company focused on developing, manufacturing and marketing a broad range of drug products. The group targets both domestic and international healthcare markets, using equity-based incentive schemes to attract and retain key talent and align management interests with shareholders.
Average Trading Volume: 110,175,637
Technical Sentiment Signal: Buy
Current Market Cap: HK$95.82B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.